Biotech | March 16, 2026
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
The decision marks a pivotal moment for the Massachusetts-based biotech giant
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Subscribe To Our Newsletter & Stay Updated
